Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IL6-receptor Inhibitor in Combination With Belumosudil for the Treatment of Belumosudil-refractory Chronic Graft-versus-host Disease (cGVHD)

NCT07484113 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT07484113
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07484113 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IL6-receptor Inhibitor in Combination With Belumosudil for the Treatment of Belumosudil-refractory Chronic Graft-versus-host Disease (cGVHD)
Lead sponsor
Stanford University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
May 31, 2028
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cgvhd